Calithera Pharma In Focus Part 1 - Checkpoint Inhibition

Clinical stage company Calithera presents an early stage investment opportunity with the ability to enhance therapeutic value to the first wave of IO therapeutics checkpoint inhibitors from Merck's Keytruda and Bristol-Myers Squibb's Opdivo.